Louisiana Medicaid
Axatilimab-csfr (Niktimvo™)

The *Louisiana Uniform Prescription Drug Prior Authorization Form* should be utilized to request clinical authorization for axatilimab-csfr (Niktimvo™).

Additional Point-of-Sale edits may apply.

By submitting the authorization request, the prescriber attests to the conditions available HERE.

Approval Criteria for Initiation of Therapy

- The recipient is 2 years of age or older on the date of the request; **AND**
- The recipient weighs at least 40 kg (88 lbs) [weight of recipient must be **stated on the request**]; **AND**
- The recipient is post-allogeneic hematopoietic cell transplant (HCT), and this is **stated on the request**; **AND**
- The recipient has a diagnosis of chronic graft-versus-host disease (chronic GVHD); **AND**
- The recipient failed treatment with at least **TWO** prior lines of systemic therapy for the treatment of chronic GVHD (e.g., corticosteroids, calcineurin inhibitors, ibrutinib, MMF, methotrexate, rituximab) (**Medication names and dates must be stated on the request**); **AND**
- The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a hematologist or oncologist.

Approval Criteria for Continuation of Therapy

- The prescriber **states on the request** that the recipient is established on the medication with evidence of a positive response to therapy.

Duration of approval for initiation and continuation of therapy: 6 months

References

ClinicalTrials.gov. A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) (AGAVE-201). https://www.clinicaltrials.gov/study/NCT04710576

Niktimvo (axatilimab-csfr) [package insert]. Wilmington, DE: Incyte Corporation; January 2025. https://www.niktimvo.com/niktimvo-prescribing-information

Saidu NEB, Bonini C, Dickinson A, Grce M, Inngjerdingen M, Koehl U, Toubert A, Zeiser R and Galimberti S (2020) New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions. Front. Immunol. 11:578314. doi: 10.3389/fimmu.2020.578314

Revision / Date	Implementation Date
Policy Created / February 2025	August 2025